The Clinical Liver Safety Assessment Best Practices Workshop: Rationale, Goals, Accomplishments and the Future

Drug Safety

Volumn 37, Issue 1, 2014, Pages 1-7

  Watkins, Paul B ^a,b   Merz, Michael ^c   Avigan, Mark I ^d   Kaplowitz, Neil ^e   Regev, Arie ^f   Senior, John R ^d  

^a Hamner University of North Carolina Institute for Drug Safety Sciences   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUMIRACOXIB; TROGLITAZONE;

BLOOD CHEMISTRY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DATA COLLECTION METHOD; DRUG INDUSTRY; DRUG SAFETY; EDISH; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; INFORMATION PROCESSING; LIVER; LIVER INJURY; LIVER TOXICITY; MOTIVATION; NATIONAL HEALTH ORGANIZATION; RISK ASSESSMENT; STANDARDIZATION; STATISTICAL MODEL; SYSTEMS BIOLOGY; TOXIC HEPATITIS; WORKSHOP; ANIMAL; DRUG DESIGN; DRUG-INDUCED LIVER INJURY; ECONOMICS; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG INDUSTRY; DRUG-INDUCED LIVER INJURY; HUMANS; RISK ASSESSMENT;

EID: 84919913722     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0181-8     Document Type: Editorial

References (22)

1. Sams-Dodd F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov Today. 2013;18:211–7.
2. Herper M. The truly staggering costs of inventing new drugs. In: Forbes. 2012. http://www.forbes.com/forbes/2012/0312/strategies-pharmaceuticals-lilly-stagger-cost-inventing-new-drugs.html. Accessed 1 April 2014.
3. Van der Graaf R, Roes KC, Van Delden JJ. Adaptive trials in clinical research: scientific and ethical issues to consider. JAMA. 2012;307:2379–80.
4. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338:916–7.
5. Garcia S, Freitas AA. Humanized mice: current states and perspectives. Immunol Lett. 2012;146:1–7.
6. Kaplowitz N. Avoiding idiosyncratic DILI: two is better than one. Hepatology. 2013;58:15–7.
7. Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012;92:332–9.
8. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests? Clin Pharmacol Ther. 2009;85:331–4.
9. FDA. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. In: US FDA guidances (drugs). 2000. http://www.fda.gov/downloads/Drugs/../Guidances/UCM174090.pdf. Accessed 1 April 2014.
10. Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther. 2011;89:788–90.
11. Babre DK. Clinical data interchange standards consortium: a bridge to overcome data standardisation. Perspect Clin Res. 2013;4:115–6.
12. Novack GD. What does the Food and Drug Administration safety and innovation act mean for you? Ocul Surf. 2013;11:206–9.
13. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34:243–52.
14. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin N Am. 2014;98:17–38.
15. Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky K, Haines L, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32:83–9.
16. Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, Barnes M. Preparing for responsible sharing of clinical trial data. N Engl J Med. 2013;369:1651–8.
17. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology. 2004;40:773.
18. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42:711–4.
19. Pharmacogenomics Reporter. Novartis eyeing US market for Prexige launch with companion test in Genomeweb. 2010. http://www.genomeweb.com/dxpgx/novartis-eyeing-us-market-prexige-launch-companion-test Accessed 1 April 2014.
20. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29:667–73.
21. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8:186–95.
22. Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today. 2009;14:162–7.